1. Home
  2. NCL vs XBIO Comparison

NCL vs XBIO Comparison

Compare NCL & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northann Corp.

NCL

Northann Corp.

HOLD

Current Price

$0.16

Market Cap

8.5M

Sector

N/A

ML Signal

HOLD

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

N/A

Current Price

$2.81

Market Cap

7.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCL
XBIO
Founded
2013
N/A
Country
United States
United States
Employees
N/A
2
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
7.2M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
NCL
XBIO
Price
$0.16
$2.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
201.0K
9.4K
Earning Date
04-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
51.43
N/A
EPS
N/A
N/A
Revenue
$15,349,854.00
N/A
Revenue This Year
N/A
$2.81
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.86
N/A
52 Week Low
$0.10
$1.90
52 Week High
$1.47
$13.93

Technical Indicators

Market Signals
Indicator
NCL
XBIO
Relative Strength Index (RSI) 51.93 45.17
Support Level $0.14 $2.90
Resistance Level $0.16 $3.12
Average True Range (ATR) 0.01 0.19
MACD 0.00 -0.03
Stochastic Oscillator 68.29 28.43

Price Performance

Historical Comparison
NCL
XBIO

About NCL Northann Corp.

Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, Benchwick. The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Share on Social Networks: